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Abstract
Background: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) after completion of systemic
adjuvant treatment predicts reduced survival in breast cancer. The present study explores the use of DTCs to
identify adjuvant insufficiently treated patients to be offered secondary adjuvant treatment intervention, and as a
surrogate marker for therapy response.
Methods: A total of 1121 patients with pN1-3 or pT1c/T2G2-3pN0-status were enrolled. All had completed primary
surgery and received 6 cycles of anthracycline-containing chemotherapy. BM-aspiration was performed 8-12 weeks
after chemotherapy (BM1), followed by a second BM-aspiration 6 months later (BM2). DTC-status was determined
by morphological evaluation of immunocytochemically detected cytokeratin-positive cells. If DTCs were present at
BM2, docetaxel (100 mg/m2, 3qw, 6 courses) was administered, followed by DTC-analysis 1 month (BM3) and
13 months (BM4) after the last docetaxel infusion.
Results: Clinical follow-up (FU) is still ongoing. Here, the descriptive data from the study are presented. Of 1085
patients with a reported DTC result at both BM1 and BM2, 94 patients (8.7%) were BM1 positive and 83 (7.6%) were
BM2 positive. The concordance between BM1 and BM2 was 86.5%. Both at BM1 and BM2 DTC-status was
significantly associated with lobular carcinomas (p = 0.02 and p = 0.03, respectively; chi-square). In addition,
DTC-status at BM2 was also associated with pN-status (p = 0.009) and pT-status (p = 0.03). At BM1 28.8% and 12.8%
of the DTC-positive patients had ≥2 DTCs and ≥3 DTCs, respectively. At BM2, the corresponding frequencies were
47.0% and 25.3%. Of 72 docetaxel-treated patients analyzed at BM3 and/or BM4, only 15 (20.8%) had persistent
DTCs. Of 17 patients with ≥3 DTCs before docetaxel treatment, 12 patients turned negative after treatment (70.6%).
The change to DTC-negativity was associated with the presence of ductal carcinoma (p = 0.009).
Conclusions: After docetaxel treatment, the majority of patients experienced disappearance of DTCs. As this is not
a randomized trial, the results can be due to effects of adjuvant (docetaxel/endocrine/trastuzumab) treatment
and/or limitations of the methodology. The clinical significance of these results awaits mature FU data, but indicates
a possibility for clinical use of DTC-status as a residual disease-monitoring tool and as a surrogate marker of
treatment response.
Trial registration: Clin Trials Gov NCT00248703
* Correspondence: bna@ous-hf.no
11Department of Oncology, Oslo University Hospital, Oslo, Norway and K.G.
Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine,
University of Oslo, Oslo, Norway
Full list of author information is available at the end of the article
© 2012 Synnestvedt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Synnestvedt et al. BMC Cancer 2012, 12:616
http://www.biomedcentral.com/1471-2407/12/616
Background
The introduction of systemic adjuvant therapy has
improved the survival of patients with early breast can-
cer. However, there is a lack of established tools to
measure the direct effect of a given systemic treatment
on minimal residual disease/micrometastases after pri-
mary surgery.
Techniques for identification and characterization of
disseminated tumor cells may open possibilities for pre-
diction of treatment response and tailored treatment
decisions. Immunocytochemical detection (ICC) of dis-
seminated tumor cells (DTCs) in the bone marrow (BM)
and further analyses of these cells have been introduced
as means to meet these needs [1-9]. Moreover, presence
of DTCs during relapse-free follow-up (+/- tamoxifen)
has been found to be a strong predictor of systemic re-
lapse and breast cancer death [10-12]. Similar results
were also reported in two smaller studies analyzing DTC
status in very high-risk breast cancer patients early after
completion of chemotherapy [1,13]. The presence of
DTCs after chemotherapy clearly indicates a rationale
for testing of alternative (secondary) treatment approaches.
Detection of DTCs following treatment intervention
should also be further tested for potential value as a
surrogate marker for future relapse/treatment effect.
During the last decade, docetaxel has been established
as a highly active treatment against breast cancer.
Response rates of 40-50% have regularly been reported
in the metastatic setting [14,15]. Prior to the initiation
of this study, results from several trials indicated that
use of docetaxel in addition to anthracycline could im-
prove the outcome of patients compared to non-taxane
regimens [16-18].
In the current study, DTC-status was monitored after
completion of anthracycline-containing adjuvant chemo-
therapy and used to identify high-risk patients as candi-
dates for secondary treatment with docetaxel. The
BM-status was analyzed 2-3 months (BM1) and 8-
9 months after chemotherapy (BM2). To reduce inclu-
sion of patients who might be in the process of gradual
eradication of DTCs caused by an effective standard
treatment, BM2 was chosen as the time point for decision
about docetaxel treatment. There was also some support
from previous studies to assess BM-status between 6 and
12 months after chemotherapy [13,19]. DTC-status was
also explored as a surrogate marker for response by moni-
toring changes in DTCs after the docetaxel treatment. The
clinical follow-up is still ongoing. Here, we present the
descriptive data from the study.
Methods
Patients
A total of 1121 patients with node positive or high-risk
node negative disease (pT1c/T2G2-3pN0) were enrolled
in the period from October 2003 to May 2008 at 7
hospitals in Norway. All patients had completed pri-
mary surgery and 6 cycles of adjuvant anthracycline-
containing chemotherapy (FEC: 5-FU 600 mg/m2,
epirubicin 60-100 mg/m2 and cyclophosphamide
600 mg/m2 3qw). Patients between 18-70 years with
no earlier or concomitant carcinoma (other than
breast carcinoma), except for basal cell carcinoma of
the skin and in situ cervix cancer, were eligible if they
had completed staging analysis including chest X-ray,
bone scintigraphy or MRI, liver ultrasound or liver CT
scan, without presence of metastases. The study was
approved by the Regional Ethical Committee (refer-
ence number S-03032). Written consent was obtained
from all patients. The study is registered in Clin Trials
Gov (registration number NCT00248703).
Patients with estrogen receptor (ER) and/or proges-
teron receptor (PR) positive tumors received endocrine
treatment according to standard recommendations at
the time of the study (tamoxifen for 5 years; tamoxifen
for 2-3 years followed by aromatase inhibitor for 2-
3 years for postmenopausal patients from 2005). From
June 2005, patients with HER2-positive tumors received
trastuzumab every 3rd week for 1 year. This treatment
was started after completion of radiotherapy. No
patients received bisphosphonates as adjuvant treatment.
Study design
The first BM-aspiration was performed at the end of ra-
diation therapy or 8-12 weeks after standard adjuvant
chemotherapy (BM1). A second BM-aspiration was per-
formed 6 months later (BM2). Bone marrow was aspi-
rated from posterior iliac crest bilaterally (5 ml from
each site) in local anaesthesia. The processing of BM
and method for DTC-analysis were performed as previ-
ously described [20]. If DTC-positive at BM2, the patient
received docetaxel (100 mg/m2 i.v., 3qw, 6 courses).
Docetaxel-treated patients were reexamined at the inclu-
sion hospital with new BM-analysis at approximately
1 month (BM3) and 13 months (BM4) after the last
docetaxel infusion. Irrespective of the DTC-status at
BM2, all patients are controlled at 6-12 months interval.
Study overview is shown in Figure 1. Statistical analyses
that include clinical outcome are first allowed after com-
pletion of follow-up and database lock. The follow-up is
still ongoing.
Preparation of bone marrow mononuclear cell samples
and detection of DTC
The BM was processed as described previously [20]. The
BM-aspirates were pooled and separated by density cen-
trifugation, mononuclear cells were collected and resus-
pended to 1×106 cells/ml. Cytospins were prepared by
centrifugation of the BM mononuclear cells (MNC)
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down to poly-L-lysine-coated glass slides (5 × 105 MNC/
slide), air-dried over night and stored at -80°C until
immunostaining.
Prior to immunostaining, the cytospins were fixed for
10 min in acetone. Briefly, four slides (totally 2 × 106
BM MNC) were incubated with the anti-cytokeratin
monoclonal antibodies (mAbs) AE1 (Millipore, prod.no.
MAB1612) and AE3 (Millipore, prod.no. MAB1611). In
parallel, the same numbers of slides (2 × 106 BM MNC)
were incubated with the same concentration of a nega-
tive control mAb of same isotype (IgG1; MOPC21,
Sigma, prod. no. M9269). The visualization step included
incubation with polyclonal rabbit anti-mouse immuno-
globulins followed by preformed complexes of alkaline
phosphatase/monoclonal mouse anti-alkaline phosphat-
ase (APAAP detection system, Dako). The color reaction
was developed by incubation with New Fuchsin solution
containing naphtol-AS-BI phosphate and levamisole,
and the slides were counterstained with hematoxylin for
30 seconds to visualize nuclear morphology.
The slides were screened by an automated microscopy
screening device (Ariol SL50, Applied Imaging), or
screened manually in light microscopy. Candidate immuno-
positive cells selected by the automated screening were
reviewed by a pathologist (E.B.). Immunopositive cells with
morphology compatible with tumor cells and/or lacking
hematopoietic characteristics were recorded as positive,
according to the recommended guidelines [10,12,21,22]. If
morphologically similar cells were detected both in the spe-
cific test and in the corresponding negative control, the
result was regarded as DTC-negative. In a different
cohort [20], we have tested the prognostic significance
of these “double positive cases”, and no difference in
clinical outcome compared to DTC-negative cases was
observed (unpublished observations). In case of inde-
terminate cell morphology a second pathologist was
consulted and consensus obtained. In doubtful cases,
16 additional cytospins were analyzed by the same ICC
method (8 slides stained with AE1/AE3 mAbs and 8
slides stained with the MOPC21 control mAb).
Analysis of primary tumor and axillary lymph node
Analysis of the primary tumors and the sentinel nodes/
axillary lymph nodes were processed on a routine
Operation
Adjuvant chemotherapy
Radiotherapy (if indicated)
BM aspiration #1   (n=1121)  
BM aspiration #2 (n=1090)
BM negative (n=1007)
Clinical follow-up
BM aspiration #3 (n=71) 
1 month post-treatment
BM aspiration #4  (n=64)
13 months post-treatment
Clinical follow-up
31 end of study
• 2 death
• 13 recurrence before BM2
• 14 consent withdrawn
• 1 excluded because of neutropenia
• 1 withdrawn because of BM aspiration 
not possible within time limit
3 end of study
• 3 death
2 BM3/BM4 not performed due to patients refusal
1 BM2 positive did incorrectly not receive treatment
7 end of study
• 4 death
• 3 recurrence before BM4
1 BM4 not done due to patient refusal
BM positive (n=83)
Docetaxel treatment
BM aspiration #3 not 
performed in 1 patient
5 with unsuccessful BM 
aspiration
1 with unsuccessful BM 
aspiration
5 end of study
• 4 recurrence before BM2
• 1 consent withdrawn
Figure 1 Study overview and enrollment.
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diagnostic basis. Histological tumor type, tumor size,
and nodal involvement were analyzed and the disease
was staged according to the tumor-node-metastasis
(TNM) system (Union Internationale Contre le Cancer
1997). Tumor grading was performed according to
Elston and Ellis [23]. The ER, PR and HER2 analyses
were performed at the participating hospitals as part of
the primary diagnostics. Immunohistochemical analyses
for ER and PR receptors in primary tumors were per-
formed according to the standard procedure in Norway
at the time of the study and considered positive if > 10%
of tumor cells stained positive with anti-ER- and/or anti-
PR antibodies. The HER2 analysis was introduced as
part of clinical routine from about June 2005, in parallel
with the inclusion of trastuzumab into the adjuvant
treatment guidelines for HER2-positive patients. Access-
ible HER2 results of the patients enrolled from this time
period on have been obtained.
Statistics
The SPSS software (version 18) was used for all statis-
tical analyses. Chi-square-based tests were used for cal-
culation of p-values for the association between baseline
characteristics and bone marrow results. For all statis-
tical calculations the Exact Sig. (2-sided) were used as
follows: Fisher Exact test for variables with two categor-
ies; Linear-by-Linear Association for variables with more
than two categories.
Results
Characteristics of the study and patients
The study overview and patient enrollment are illu-
strated in Figure 1 and the clinico-pathological features
of the patients are shown in Table 1. The median age at
inclusion was 48 years (range 23-69 years). Most of these
patients had pT1c and pT2 tumors, (46.7% and 41.9%
respectively) and the majority was grade 2 or 3 tumors
(53.9% and 37.3% respectively). Infiltrating ductal carcin-
oma constituted 82.4% of the cases, while 9.8% were
lobular carcinomas. Estrogen receptors were expressed
in 75.2% of the cases, and 17.4% of the patients analysed
for HER2 (from June 2005) were positive. Lymph node
status was negative in 43.3% of the patients. Of those
with presence of axillary metastases 2/3 were pN1.
DTC detection at BM1 and BM2
Out of 1085 patients with a reported DTC result for
both BM1 and BM2, 94 (8.7%) and 83 patients (7.6%)
were BM1 and BM2 positive, respectively (Table 1). The
concordance between BM1 and BM2 was 86.5%. Among
the BM1 positive patients, only 15 (16.0%) were BM2
positive, a result that may be affected by the recent ad-
ministration of the standard adjuvant chemotherapy.
Moreover, a change from BM1 positive to BM2 negative
DTC-status was observed in 82.4% (61/74) of the endo-
crine treated patients, in 87.5% (7/8) of the trastuzumab
treated patients (4 of the patients were treated with both
endocrine therapy and trastuzumab) and in 85.7% (6/7)
of the patients that did not receive endocrine treatment
or trastuzumab. Presence of DTCs at BM1 was signifi-
cantly associated with lobular carcinoma (p = 0.02) and
BM2-status (p = 0.004), and borderline significance was
observed for pT-status (p = 0.06) and histological grade
(p = 0.06). At BM2, DTC-status was associated with
pN-status (p = 0.009), pT-status (p = 0.03) and lobular
carcinoma (p = 0.03). At BM1 28.8% of the DTC-positive
patients had ≥2 DTCs, and 12.8% harboured ≥3 DTCs.
At BM2, ≥2 DTCs were detected in almost half (47.0%)
of the patients, whereas 25.3% had ≥3 DTCs (Table 2).
DTC-monitoring and tumor characteristics in docetaxel
treated patients
Patients with BM2 positivity received docetaxel treat-
ment. BM-aspiration post-treatment was performed if at
least 4 cycles with docetaxel were administered. A
presentation of the absolute numbers of DTCs (categorized
as 0, 1, 2, 3-9 or ≥10 DTCs) at BM2, BM3 and BM4 is
shown in Additional file 1: Figure S1 and Additional file 2:
Table S1. At BM3 DTC-status turned negative in 59 of 71
cases (83.0%), and 53 of 64 were negative at BM4 (82.8%)
(Table 3). In 19 of the patients BM-aspiration was not per-
formed at BM3 and/or BM4, as explained in Figure 1. Of
72 patients categorized according to the last (of BM3 or
BM4) performed BM-aspiration, only 15 (20.8%) had per-
sistent DTCs after docetaxel treatment (Table 3). Of 17
patients with ≥3 DTCs before docetaxel treatment, only 5
patients were positive after treatment (29.4%).
Subgroup analyses of patients with persistent DTCs
after treatment compared to those with negative DTC-
status after treatment are shown in Table 4. The change
to negative DTC-status was significantly associated with
ductal carcinoma histology (p = 0.009). For the other
clinico-pathological parameters there were no significant
associations. Furthermore, as shown in Additional file 3:
Table S2, patients with ≥3 DTCs before treatment (i.e. at
BM2) who turned DTC-negative after treatment, had
similar characteristics as all the patients achieving nega-
tive DTC-status.
For the patients with DTC presence at BM1 and/or
BM2, the DTC results at all performed time points, to-
gether with the endocrine and trastuzumab treatment
status, are listed in Additional file 4: Table S3.
Discussion
The present study is, to our knowledge, the first
reported study to use DTC-status to select for and
monitor secondary adjuvant chemotherapy intervention
in breast cancer. The identification of high-risk patients
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Table 1 Clinico-pathological data of the patients and BM-status at BM1 and BM2a
All patients
Number (%)b
BM1 neg
Number (%)c
BM1 pos
Number (%)c
P valued BM2 neg
Number (%)c
BM2 pos
Number (%)c
P valued
Number: n = 1090 n = 991 n = 94 n = 1002 n = 83
Age at inclusion (median): 48 (range 23-69)
Menopausal status:
Pre 592 (55.7) 540 (91.5) 50 (8.5) 0.19 547 (92.7) 43 (7.3) 0.60
Post 325 (30.6) 287 (88.9) 36 (11.1) 296 (91.6) 27 (8.4)
Unknown 146 (13.7) 138 (95.2) 7 (4.8) 134 11 (7.6)
Missing 27 26 1 25 (92.4) 2
Primary breast cancer surgery: 1.00 0.29
Mastectomy 424 (39.4) 384 (91.2) 37 (8.8) 384 (91.2) 37 (8.8)
Lumpectomy 653 (60.6) 594 (91.2) 57 (8.8) 60612 (93.1) 45 (6.9)
Missing 13 13 1
pT-status: 0.06 0.03
pT 1a + b 67 (6.3) 55 (82.1) 12 (17.9) 65 (97.0) 2 (3.0)
pT1c 500 (46.7) 451 (90.7) 46 (9.3) 464 (93.4) 33 (6.6)
pT2 449 (41.9) 418 (93.3) 30 (6.7) 407 (90.8) 41 (9.2)
pT3 49 (4.6) 44 (91.7) 4 (8.3) 43 (89.6) 5 (10.4)
pT4 6 (0.6) 6 (100) 0 (0) 5 (83.3) 1 (16.7)
Missing 19 17 2 18 1
pN-status: 0.59 0.009
pN0 462 (43.3) 424 (92.2) 36 (7.8) 428 (93.0) 32 (7.0)
pN1 455 (42.6) 408 (89.9) 44 (9.7) 424 (93.8) 28 (6.2)
pN2 99 (9.3) 93 (93.9) 6 (6.1) 86 (86.9) 13 (13.1)
pN3 52 (4.9) 46 (88.5) 6 (11.5) 43 (82.7) 9 (17.3)
Missing 22 20 2 21 1
Histology: 0.02e 0.03e
IDC 888 (82.4) 815 (92.3) 68 (7.7) 821 (93.0) 62 (7.0)
ILC 106 (9.8) 90 (84.9) 16 (15.1) 92 (86.8) 14 (13.2)
Others 84 (7.8) 74 (88.1) 10 (11.9) 79 (94.0) 5 (6.0)
Missing 12 12 10 2
Histological grade: 0.06 0.92
Grade 1 83 (7.7) 75 (90.4) 8 (9.6) 80 (96.4) 3 (3.6)
Grade 2 583 (53.9) 520 (89.8) 59 (10.2) 527 (91.0) 52 (9.0)
Grade 3 404 (37.3) 378 (93.8) 25 (6.2) 376 (93.3) 27 (6.7)
Unclassified 12 (1.2) 117 (91.7) 1 (8.3) 12 (100) 0 (0)
Missing 8 1 7 1
ER-status: 0.20 0.69
Pos 814 (75.2) 737 (91.0) 73 (9.0) 749 (92.5) 61 (7.5)
Neg 268 (24.8) 250 (93.6) 17 (6.4) 245 (91.8) 22 (8.2)
Missing 8 4 4 8
PR-status:
Pos 701 (64.9) 636 (91.1) 62 (8.9) 0.91 648 (92.8) 50 (7.2) 0.34
Neg 369 (34.2) 337 (91.6) 310 (8.4) 3359 (91.0) 33 (9.0)
Unclassified 10 (1.0) 9 (100) 1 (0) 10 (100) 0 (0)
Missing 10 9
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for future relapse, at a time point where otherwise no
additional prognostic information can be achieved from
standard histopathological/clinical assessment, is attractive.
This opens for testing of alternative treatment strat-
egies in a “window of opportunity” for potential eradi-
cation of minimal residual disease. The results show
that persistent DTCs 8-9 months after 6 courses of FEC
chemotherapy are changed to DTC-negativity in 79.2%
of the cases following secondary treatment with doce-
taxel. This indicates a potential for docetaxel to eradi-
cate minimal residual disease burden in high-risk
patients. It cannot be excluded that presence of 1 DTC
can be followed, by chance, by a negative result in the
next test (Poisson distribution and/or methodological
limitations). However, persistent negativity at two time
points, and especially the fact that ¾ of the patients
with ≥3 DTCs at BM2 turned negative at BM3/4, sug-
gest a change in the tumor cell load after the interven-
tion. The recent meta-analysis of 14 randomized
clinical trials by Jean-Philippe Jacquin et al [24], sup-
port a clear additional effect of docetaxel-containing
adjuvant chemotherapy to a non-taxane-containing
regimen in patients with early stage breast cancer (HR
0.84 (95% CI 0.78-0.89; P < 0.001) for DFS and 0.86 (0.78-
0.94; P < 0.001) for OS). The benefit is consistent across
all patient subgroups, although proliferation status was
not analyzed. These results may support an association
between the docetaxel secondary adjuvant treatment and
the reduction in DTC-positivity in our study.
The subgroup analysis shown in Table 4 reveals a sig-
nificant difference in the fate of DTCs after docetaxel
treatment according to histological tumor subtype. Half
of the patients with lobular carcinoma had persistent
DTCs, as compared to 15% of the ductal carcinoma
patients. This observation is in line with a reported
relative chemotherapy resistance for lobular carcinoma
[25-27], and adds further support to the possibility of
docetaxel-induced changes in the observed DTC-status.
Furthermore, a higher fraction of patients with DTC-
positive status at BM1 seemed to have persistence of
DTCs after the treatment, although statistical signifi-
cance was not reached (p = 0.11). It may be speculated
whether a proportion of these patients have a more re-
sistant disease (i.e. less fluctuations of DTCs despite
chemotherapy). It is known from several studies that
patients with primary resistance to first line chemother-
apy also have a higher risk of not responding to second
line treatment [28,29]. The clinical outcome of the
patients included in the present study needs to be
awaited, before further interpretation of the results.
The analysis of BM2 showed that DTC-status was
associated with pN-status and pT-status (Table 1). The
same was reported in a different study from our group,
Table 2 Number of DTCs detected in BM1 and BM2
positive cases
Number of DTCs BM1
Number (%)
BM2
Number (%)
1 67 (71.3) 44 (53.0)
2 15 (16.0) 18 (21.7)
3-9 9 (9.6) 12 (14.5)
≥10 3 (3.2) 9 (10.8)
Table 1 Clinico-pathological data of the patients and BM-status at BM1 and BM2a (Continued)
All patients
Number (%)b
BM1 neg
Number (%)c
BM1 pos
Number (%)c
P valued BM2 neg
Number (%)c
BM2 pos
Number (%)c
P valued
Endocrine therapy: 0.52 0.41
Yes 810 (76.2) 733 (90.8) 74 (9.2) 750 (92.9) 57 (7.1)
No 253 (23.8) 233 (92.5) 19 (7.5) 230 (91.3) 22 (8.7)
Missing 27 25 1 22 4
HER2-statusf: 0.46 0.84
Pos 117 (17.4) 109 (94.0) 7 (6.0) 108 (93.1) 8 (6.9)
Neg 557 (82.6) 507 (91.4) 48 (8.6) 519 (93.5) 36 (6.5)
Missing 51 48 2 49
BM1:
Positive 79 (84.0) 15 (16.0) 0.004
Negative 923 (93.1) 68 (6.9)
aAll patients with a BM2 result are presented (column all patients). For the data according to BM1 and BM2 status, patients with a reported result on both
analyses, are presented, n = 1085) (also see Figure 1).
bValid percent.
cThe percentages for the BM1 and BM2 analysis, in relation to the clinico-pathological variables.
dFisher Exact test for variables with two categories; Linear-by-Linear Association for variables with more than two categories.
“Unknown”, “Others”, Missing and “Unclassified” are not included in the statistical analysis.
eComparison of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
fPatients enrolled from June 2005 (n = 725); HER2 testing was not performed routinely before this time point.
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analyzing DTC-status 3 years after diagnosis [12]. In this
previous study it was also observed that DTC-positivity
was positively associated with lobular carcinoma, which
can be explained by a relative resistance also to the
anthracycline-containing chemotherapy [25,30]. Our study
supports the selection of higher stage patients into future
DTC intervention trials (Table 1), in order to select those
with both the traditionally highest risk of relapse and the
highest frequency of DTC-positivity. A consideration of
the histological type may also be of importance, for selec-
tion to the proper type of systemic treatment to the right
tumor subtype.
The testing of novel therapeutical principles or drugs
is highly resource demanding. In addition, the effect of a
new adjuvant treatment can only be evaluated when a
relapse occurs, often several years later. The need for
surrogate/intermediate markers to predict and monitor
the therapeutic effect is obvious, but needs to be thor-
oughly validated. The present study is an initial step to
explore the possibility to use DTCs in BM as a monitor-
ing tool. Other possible approaches could be monitoring
of circulating tumor cells (CTCs) or, as very recently
reported, analysis of circulating tumor DNA in plasma/
serum [31]. Detection of CTCs was not a part of the
current study, because no standardized CTC-method
was available at the time of study start. The performed
repeated BM-analyses, however, were feasible and ac-
ceptable for the large majority of the patients.
The observed frequency of DTCs in the BM was mark-
edly lower than what was expected prior to the study.
This might be due to the assay sensitivity, but may have
several additional explanations. The previously reported
studies of DTCs have mostly been performed on BM-
aspirates at the time of primary surgery. The subsequent
administration of adjuvant chemotherapy might give a
reduction in DTC-positivity. Furthermore, recent stud-
ies, using more standardized criteria, generally have
shown lower DTC-positivity rates [12,20,22,32,33] than
those reported in older studies. Additionally, there has
been a stage migration after introduction of organized
mammography screening (which is established in Norway),
which probably results in less patients with micrometastatic
disease. In our study, all the patients were screened
for metastases before inclusion, which also might have
affected the frequency of DTC presence. Finally, we
used a conservative approach for inclusion of patients
to docetaxel treatment in the current study. Doubtful
cases were concluded as DTC-negative. It is possible
to increase the sensitivity by analyzing larger number
of cells (higher BM-volume). However, the clinical sig-
nificance of DTC-status at primary surgery was not
increased by analyzing more cells in our previous
study [34]. Use of larger volumes of BM, or larger
numbers of BM MNC, might require additional
characterization of the detected DTCs, in order to
identify markers of DTC aggressiveness and to secure
both sensitivity and specificity. Accordingly, available
FISH, CGH and multi-marker analyses may improve
the utility of DTCs as a surrogate marker for response
[33,35-39]. Characterization of the DTCs also opens
for studies of tumor dormancy, EMT, stemness and/or
identification of treatment targets.
The present study does not allow a direct interpretation
of the effect of docetaxel on DTC-status. Although a rando-
mized approach would have been the optimal design for
this purpose, we chose the current design to explore the
clinical potential for DTC-directed intervention. A rando-
mized trial would raise several concerns, if performed un-
blinded to the DTC-status. To inform the patients about a
DTC-positivity without intervention (in one arm) was con-
sidered ethically difficult. A blinded study (blinded
randomization of both DTC-negative and DTC-positive
patients to no additional versus docetaxel treatment) was
found to be premature without supporting data and would
have needed a very large and expensive study. Recently a
randomized trial was reported for DTC positive early breast
cancer patients at diagnosis, where patients received
chemotherapy +/- zoledronic acid. The results showed
improved elimination of DTCs in patients treated with
zoledronic acid [40]. In another study in locally advanced
breast cancer, DTC status was also affected by the adminis-
tration of zoledronic acid [41]. Although clinical outcome
results have not yet been reported, these data support the
potential use of DTCs as a monitoring tool. In our study,
Table 3 Number of DTCs detected before (BM2) and after docetaxel treatment (BM3/BM4) in BM2-positive patientsa
Number of DTCs BM2
Number (%)
BM3
Number (%)
BM4
Number (%)
Last post-treatment
BM result
Number (%)
0 59 (83.1) 53b (82.8) 57 (79.2)
1 39 (54.1) 7 (9.9) 9 (14.1) 9 (12.5)
2 16 (22.2) 1 (1.4) 1 (1.6) 2 (2.8)
≥3 17 (23.6) 4 (5.6) 1 (1.6) 4 (5.6)
Not performed 1 8
aOnly patients with DTC results at BM3 and/or BM4 are included (see Figure 1).
bThree samples classified as negative with morphologically similar cells detected in the corresponding negative control.
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comparison to clinical end points has to await completion
of the follow-up.
We chose 8-9 months after the standard adjuvant
chemotherapy as time point for the DTC-analysis de-
cisive for secondary adjuvant treatment. This was par-
tially based on the results of the SBG study [13], where a
positive DTC-status 6 months after chemotherapy identi-
fied patients with very poor prognosis. Furthermore, Slade
et al performed repetitive BM-analyses at follow-up and
found that the frequency of DTC-positive events was high-
est at 12 months after surgery [19]. Considering the in-
creasing support for a detrimental outcome of patients
with a positive DTC-status at later time points during
follow-up [11], it might be an even more optimal ap-
proach to perform serial BM-aspirations during the
first follow-up years, and to test secondary intervention
Table 4 Analyses of clinico-pathological data and DTC-status after treatmenta
Histopathology All patients
Number (%)b
Persistent DTC
after treatment
Number (%)c
Negative for DTC
after treatment
Number (%)c
P valued
Number: n=72 n=15 n=57
pT-status:
pT1a +b 2 (2.8) 0 (0) 2 (100)
pT1c 29 (40.3) 6 (20.7) 23 (79.3) 0.80
≥pT2 41 (56.9) 9 (22.0) 32 (78.0)
Histology:
IDC 54 (76.1) 8 (14.8) 46 (85.2)
ILC 14 (19.7) 7 (50.0) 7 (50.0) 0.009e
Others 3 (4.2) 0 (0) 3 (100)
Missing 1 0 1
ER-status:
Posf 54 (75.0) 13 (24.1) 41 (75.9) 0.33
Neg 18 (25.0) 2 (11.1) 16 (88.9)
PR-status:
Posf 46 (63.9) 8 (17.4) 38 (82.6) 0.38
Neg 26 (36.1) 7 (26.9) 19 (73.1)
BM1:
Pos 13 (18.1) 5 (38.5) 8 (61.5) 0.11
Neg 59 (81.9) 8 (14.5) 47 (85.5)
pN-status:
pN0 28 (39.4) 4 (14.3) 24 (85.7) 0.37
pN+ 43 (60.6) 11 (25.6) 32 (74.4)
Missing 1 0 1
Histological grade:
Grade1-2 51 (71.8) 12 (23.5) 39 (76.5) 0.53
Grade3 20 (28.2) 3 (15.0) 17 (85.0)
Missing 1 0 1
HER2-statusg:
Pos 6 (15.8) 0 (0) 6 (100) 0.57
Neg 32 (84.2) 7 (21.9) 25 (78.1)
Missing 1 1
aOnly patients with DTC results at BM3 and/or BM4 are included (see Figure 1).
bValid percent.
cThe percentages in relation to the clinico-pathological variables.
dFisher exact.
eComparison of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
fPatients with positive ER and/or PR-status received endocrine treatment.
gPatients enrolled from June 2005 (n = 39). Patients with positive HER2-status received trastuzumab.
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whenever a DTC-positive status appear. This might be
a reasonable consideration for future studies.
Conclusions
DTC-analysis can be a useful tool for identifying patients
who do not respond to a chosen standard adjuvant therapy
and accordingly should be tested for benefit of additional
secondary adjuvant therapy. Elimination of DTCs after
docetaxel treatment was observed in the majority of the
patients. Although the clinical significance of these results
awaits mature follow-up data, the current study presents a
novel potential approach for optimized adjuvant treatment
of breast cancer, supporting further exploration of this
intervention principle.
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